Financial reports
10-Q
2024 Q1
Quarterly report
9 May 24
10-K
2023 FY
Annual report
8 Mar 24
10-Q
2023 Q3
Quarterly report
3 Nov 23
10-Q
2023 Q2
Quarterly report
4 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
10-K
2022 FY
Annual report
10 Mar 23
10-Q
2022 Q3
Quarterly report
4 Nov 22
10-Q
2022 Q2
Quarterly report
5 Aug 22
10-Q
2022 Q1
Quarterly report
6 May 22
10-K
2021 FY
Annual report
11 Mar 22
Current reports
8-K
Other Events
28 May 24
8-K
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
8 May 24
8-K
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYUâ„¢ in Non-Proliferative Diabetic Retinopathy
6 May 24
8-K
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
7 Mar 24
8-K
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
4 Mar 24
8-K
Results of Operations and Financial Condition
10 Jan 24
8-K
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
8 Dec 23
8-K
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
7 Dec 23
8-K
Other Events
4 Dec 23
8-K
Other Events
9 Nov 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
7 Dec 23
424B5
Prospectus supplement for primary offering
4 Dec 23
S-3
Shelf registration
20 Oct 23
S-8
Registration of securities for employees
20 Oct 23
S-8
Registration of securities for employees
9 Jan 23
424B5
Prospectus supplement for primary offering
18 Nov 21
FWP
Free writing prospectus
17 Nov 21
424B5
Prospectus supplement for primary offering
16 Nov 21
S-3
Shelf registration
6 Aug 21
S-8
Registration of securities for employees
6 Aug 21
Proxies
DEF 14A
Definitive proxy
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Sep 22
DEF 14A
Definitive proxy
28 Sep 22
PRE 14A
Preliminary proxy
16 Sep 22
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
DEF 14A
Definitive proxy
3 May 21
Other
EFFECT
Notice of effectiveness
31 Oct 23
CORRESP
Correspondence with SEC
26 Oct 23
UPLOAD
Letter from SEC
25 Oct 23
EFFECT
Notice of effectiveness
12 Aug 21
CORRESP
Correspondence with SEC
9 Aug 21
UPLOAD
Letter from SEC
9 Aug 21
EFFECT
Notice of effectiveness
10 May 21
CORRESP
Correspondence with SEC
5 May 21
SEC STAFF
SEC staff action: Order
5 Mar 21
UPLOAD
Letter from SEC
18 Feb 21
Ownership
4
DAVID R GUYER
16 May 24
144
Notice of proposed sale of securities
14 May 24
4
Bihua Chen
8 May 24
SC 13G/A
Adage Capital Management, L.P.
1 May 24
SC 13G
Adage Capital Management, L.P.
30 Apr 24
3
Robert Atchinson
22 Apr 24
4
Bihua Chen
22 Apr 24
4
Dario A. Paggiarino
2 Apr 24
4
Ramiro Ribeiro
4 Mar 24
3
Ramiro Ribeiro
4 Mar 24